Archived Policies - Prescription Drugs
Platelet Derived Growth Factors for Wound Healing
Becaplermin (Regranex Gel), a recombinant, platelet-derived growth factor (PDGF) may be eligible for coverage when used as an adjunct to standard wound management and used according to the FDA labeled indication (i.e., neuropathic diabetic ulcers extending into the subcutaneous tissue).
Other applications of becaplermin are considered investigational and are not eligible for coverage. These include, but are not limited to:
Platelet derived wound healing formula (Procuren) is considered investigational and is not eligible for coverage.
A variety of growth factors have been found to play a role in wound healing, including platelet derived growth factor, epidermal growth factor, fibroblast growth factors, transforming growth factors and insulin-like growth factor. Topically applied platelet derived growth factors (PDGF) have been most extensively investigated for clinical use in wound healing. The U.S. Food and Drug Administration (FDA) have recently approved a recombinant PDGF product, becaplermin (trade name Regranex Gel, McNeil Pharmaceutical). The labeled indication is as follows:
Becaplermin (Regranex Gel) is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. When used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control, Regranex Gel increases the complete healing of diabetic ulcers. The efficacy of Regranex Gel for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue or ischemic diabetic ulcers has not been evaluated."
Appropriate candidates for Becaplermin (Regranex Gel) are selected by the following criteria:
Becapleromin is available in 2-g, 7.5-g, and 15-g tubes, and is applied in a thin continuous layer, about 1/16th of an inch,( i.e., the thickness of a dime). The amount of the gel used will depend on the size of the ulcer, measured in square centimeters. However, an average-sized ulcer, measuring 3 cm, treated for an average length of time of 85 days will require a little more than one 15-g tube. If the ulcer is treated for the maximum length of time of 140 days, 1.75 15-g tubes wound are required.
Platelet derived wound healing formula (Procuren, Curative Technologies, Inc.) is an autologous product that is derived from the patients' own blood cells. This product has not undergone FDA approval. The patient's platelets are isolated by centrifugation, then exposed to thrombin, which prompts a release of a variety of growth factors. This platelet releasate is applied to the wound for a period of 12 hours, then rinsed away and followed by an application of topical antibiotics. Platelet derived wound healing formula is often offered as part of a program of wound care management as offered by Wound Care Centers, which are operated by Curative Technologies, Inc.
Chronic nonhealing ulcers of the lower extremity are a common problem and may be related to venous stasis, peripheral neuropathy, local trauma, or ischemia: three factors that are common causes for ulcers in diabetics. Standard treatment for nonhealing ulcers includes debridement, treatment of infection, avoidance of weight bearing, and revascularization in those surgical candidates with ischemic ulcers.
Becaplermin (Regranex Gel)
This policy regarding the use of Becaplermin is based on a 1999 TEC assessment that offered the following conclusions:
The evidence supports the conclusion that Becaplermin treatment, in conjunction with good wound care, improves the health outcomes of patients with chronic neuropathic diabetic ulcers that meet the patient selection criteria. Becaplermin gel plus good wound care resulted in a 43% complete wound-closure rate, compared to 28% for patients treated with good wound care alone. Becaplermin gel also appeared to reduce the average time to complete wound closure.
There is insufficient evidence to determine the effect of Becaplermin gel in treatment of other types of ulcers, including ischemic, chronic venous or chronic pressure ulcers.
It should be emphasized the beneficial effects of Becaplermin were achieved within the setting of a controlled clinical trial protocol. Results of the clinical trials clearly tied the efficacy of Becaplermin treatment to the overall intensity of the wound management effort. Variations in standard care, including infection control, debridement type and frequency, non-weight bearing compliance and methods, and patients' glycemic control all influence ulcer healing. Whether this comprehensive degree of wound care is maintained in a community practice or home care setting is a concern. The magnitude of becaplermin effect, as demonstrated in clinical trials, can be expected only in settings that adhere to good wound care practices.
Platelet Derived Wound Healing Formula (i.e., Platelet Releasate, Procuren)
The policy on platelet derived wound healing formula is derived from a 1992 TEC assessment. The TEC assessment identified two randomized clinical trials that report conflicting results such that no conclusions could be reached regarding the health benefits of platelet derived wound healing formula. A literature search extending from January 1992 to April 1999 was performed; no additional randomized studies were identified. Glover and colleagues published a 4-year retrospective study of wound healing using platelet-derived wound healing formula. Although the authors stated that patients in the treatment group reported higher healing rates compared to those treated with standard wound care alone, this uncontrolled study does not permit analysis of the independent contribution of platelet derived wound healing formula.
Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.
Growth Factors for Wound Healing BCBSA TEC Assessment Program (1992 Nov/Dec) 352-377.
Glover JL, Weingarten MS, Buchbinder DS, and et al. A 4-year outcome-based retrospective study of wound healing and limb salvage in patients with chronic wounds Adv Wound Care (1997) 10:33-38
Becaplermin for Wound Healing BCBSA TEC Assessment Program (1999 June) 14 (5): 1-27.
BCBSA Consortium Health Plan Medical Policy Reference Manual (1999 October 1) Medicine: 2.01.16
|Title:||Effective Date:||End Date:|
|Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions||04-15-2019||05-14-2020|
|Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions||11-01-2018||04-14-2019|
|Recombinant and Autologous Platelet-Derived Growth Factors as a Primary Treatment of Wound Healing and Other Miscellaneous Conditions||07-15-2017||10-31-2018|
|Recombinant and Autologous Platelet-Derived Growth Factors as a Primary Treatment of Wound Healing and Other Miscellaneous Conditions||06-01-2016||07-14-2017|
|Recombinant and Autologous Platelet-Derived Growth Factors as a Primary Treatment of Wound Healing and Other Miscellaneous Conditions||08-01-2015||05-31-2016|
|Platelet Derived Growth Factors for Wound Healing||11-01-2000||11-14-2006|